Current reports
6-K
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
26 Mar 24
6-K
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
20 Mar 24
6-K
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
18 Mar 24
6-K
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
4 Mar 24
6-K
Current report (foreign)
29 Feb 24
6-K
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
15 Feb 24
6-K
Valneva Announces Sale of Priority Review Voucher for $103 Million
5 Feb 24
6-K
Current report (foreign)
10 Jan 24
6-K
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
8 Jan 24
6-K
Valneva Provides Updated 2023 Financial Guidance
29 Dec 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
30 Sep 22
424B5
Prospectus supplement for primary offering
28 Sep 22
F-3
Shelf registration (foreign)
12 Aug 22
424B4
Prospectus supplement with pricing info
1 Nov 21
F-1
Registration statement (foreign)
26 Oct 21
DRS
Draft registration statement
20 Oct 21
424B4
Prospectus supplement with pricing info
7 May 21
F-1/A
Registration statement (foreign) (amended)
5 May 21
8-A12B
Registration of securities on exchange
3 May 21
F-1/A
Registration statement (foreign) (amended)
29 Apr 21
Proxies
No filings
Other
UPLOAD
Letter from SEC
14 Aug 23
CORRESP
Correspondence with SEC
10 Aug 23
UPLOAD
Letter from SEC
3 Aug 23
EFFECT
Notice of effectiveness
22 Aug 22
CORRESP
Correspondence with SEC
17 Aug 22
UPLOAD
Letter from SEC
16 Aug 22
EFFECT
Notice of effectiveness
29 Oct 21
CORRESP
Correspondence with SEC
26 Oct 21
CORRESP
Correspondence with SEC
26 Oct 21
UPLOAD
Letter from SEC
25 Oct 21